CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.390
-0.060 (-1.35%)
Apr 24, 2026, 11:51 AM EDT - Market open
CytomX Therapeutics Employees
CytomX Therapeutics had 69 employees as of December 31, 2025. The number of employees decreased by 52 or -42.98% compared to the previous year.
Employees
69
Change (1Y)
-52
Growth (1Y)
-42.98%
Revenue / Employee
$1,104,362
Profits / Employee
-$295,217
Market Cap
949.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | -52 | -42.98% | 69 | 0 |
| Dec 31, 2024 | 121 | -1 | -0.82% | 119 | 2 |
| Dec 31, 2023 | 122 | 4 | 3.39% | 120 | 2 |
| Dec 31, 2022 | 118 | -60 | -33.71% | 116 | 2 |
| Dec 31, 2021 | 178 | 32 | 21.92% | 174 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| KalVista Pharmaceuticals | 275 |
| Xencor | 260 |
| Geron | 258 |
| Omeros | 175 |
| Sana Biotechnology | 142 |
| Janux Therapeutics | 109 |
CTMX News
- 5 weeks ago - Why Is CytomX Therapeutics Stock Falling On Wednesday? - Benzinga
- 5 weeks ago - CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally - Benzinga
- 5 weeks ago - CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 7 weeks ago - CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - GlobeNewsWire